A number of other analysts also recently issued reports on FLDM. Zacks Investment Research downgraded Fluidigm from a “buy” rating to a “hold” rating in a research report on Tuesday, January 1st. ValuEngine upgraded Fluidigm from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Janney Montgomery Scott upgraded Fluidigm from a “neutral” rating to a “buy” rating in a research report on Thursday, January 3rd. Piper Jaffray Companies raised their price target on Fluidigm from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Finally, BTIG Research started coverage on Fluidigm in a research report on Wednesday, March 13th. They issued a “buy” rating and a $15.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.00.
FLDM stock opened at $12.83 on Friday. Fluidigm has a fifty-two week low of $4.65 and a fifty-two week high of $14.90. The company has a quick ratio of 3.04, a current ratio of 3.38 and a debt-to-equity ratio of 2.39. The firm has a market capitalization of $885.13 million, a P/E ratio of -16.04 and a beta of 2.43.
Large investors have recently added to or reduced their stakes in the company. Quantamental Technologies LLC bought a new stake in shares of Fluidigm during the fourth quarter worth $61,000. United Services Automobile Association bought a new stake in shares of Fluidigm during the fourth quarter worth $102,000. Brown Advisory Inc. bought a new stake in shares of Fluidigm during the fourth quarter worth $115,000. Bank of America Corp DE lifted its position in shares of Fluidigm by 149.3% during the fourth quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after purchasing an additional 8,654 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Fluidigm by 42.9% during the fourth quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock worth $297,000 after purchasing an additional 10,358 shares during the last quarter. Institutional investors and hedge funds own 71.65% of the company’s stock.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Story: Depreciation
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.